Last Update 02 Mar 26

BAX: Q4 Reset And 2026 Outlook Will Test Margin Recovery Hopes

Analysts have trimmed their average 12 month price target for Baxter International by several dollars into the high teens, pointing to weaker than expected 2026 margin guidance and limited near term visibility as key drivers of the reset.

Analyst Commentary

Recent research shows a clear reset in expectations for Baxter International, with most firms trimming price targets and highlighting weaker 2026 guidance as a key catalyst. Even so, there are still pockets of optimism alongside a cautious tone on execution and earnings power.

Bullish Takeaways

Bullish analysts who previously set targets in the low to mid $20s pointed to a view that earlier uncertainty around Baxter's outlook could be absorbed in the share price, suggesting some support for valuation if management delivers on its plan.
Earlier commentary indicated that clearer Q4 results and a formal 2026 outlook were expected to reduce uncertainty and could help the stock trade more in line with the underlying business profile.
Neutral ratings from major firms such as Goldman Sachs, even alongside target cuts, indicate that some on the Street still see a balanced risk and reward setup rather than a clearly negative skew.

Bearish Takeaways

Bearish analysts have lowered price targets into the high teens, pointing directly to margin pressures and higher non operating items that leave the 2026 EPS guidance mid point about 16% below the pre Q4 consensus, which weighs on earnings power and valuation support.
Several firms cited Baxter's 2026 outlook as underwhelming, with limited near term visibility, which makes it harder for investors to underwrite a stronger growth or margin recovery story.
Fresh target reductions in the current high teens and low $20s, compared with earlier targets around $30, reflect reduced confidence in Baxter's ability to hit prior margin and earnings expectations.
Repeated resets to models across the Street point to ongoing concern around execution, particularly on cost control and non operating items, which can cap how much investors are willing to pay for the shares on a P/E basis.

What's in the News

The company reported unaudited goodwill impairment charges of $485 million for the fourth quarter of 2025, compared with $425 million a year earlier, affecting reported results for that period (Impairments/Write Offs).
Baxter issued 2026 earnings guidance that calls for flat to 1% U.S. GAAP sales growth for the full year. This gives investors a reference point for expected top line trends (Corporate Guidance).
The company completed a long running share repurchase program originally announced on July 25, 2012. It bought back a total of 103,783,750 shares, or 19.57% of shares, for US$7,220.95 million, with no shares repurchased in the October to December 2025 tranche (Buyback Tranche Update).
At the 2026 J.P. Morgan Healthcare Conference, Baxter announced the upcoming U.S. launch of the Dynamo Series stretcher, a connected care product aimed at easing staff workload, reducing patient falls and improving comfort. Availability is expected in the first half of 2026 (Product Related Announcements).
MUSC Health and Baxter entered a multi year partnership focused on connected care technologies to streamline bedside workflows, support nurse satisfaction and retention, and use real time data to support quality and safety outcomes (Client Announcements).
Law firm Levi & Korsinsky notified investors of a class action securities lawsuit related to alleged issues with Baxter's Novum LVP infusion pump, including claimed device malfunctions and questions around prior company disclosures about product safety and sales prospects (Lawsuits & Legal Issues).

Valuation Changes

Fair Value: Model fair value remains unchanged at $21.63, so there is no adjustment to the central valuation level.
Discount Rate: The discount rate has edged down slightly from 9.76% to 9.72%, a small shift that modestly affects the present value of future cash flows.
Revenue Growth: The assumed long term revenue growth rate is effectively stable at about 1.95%, with only a minimal rounding change.
Net Profit Margin: The projected net profit margin stays effectively flat at about 7.57%, indicating no material reset to profitability assumptions in the model.
Future P/E: The future P/E multiple is essentially unchanged, moving marginally from 16.43x to 16.41x, so the valuation framework for Baxter International remains largely intact.

35 views

Key Takeaways

Recovery in hospital activity and patient admissions is driving higher demand for Baxter's core products, supporting potential revenue and margin growth.
Innovation and portfolio optimization, combined with new leadership, position Baxter for efficiency gains, higher-margin offerings, and long-term market share expansion.
Volume recovery and profitability are at risk due to sustained demand weakness, supply chain issues, quality concerns, and margin pressures amid ongoing operational transitions.

Catalysts

About Baxter International

Through its subsidiaries, provides a portfolio of healthcare products in the United States.What are the underlying business or industry changes driving this perspective?

Normalization of hospital purchasing patterns and patient admissions is expected to drive increased utilization of Baxter's core IV solutions and infusion systems as fluid conservation efforts abate, providing upside to revenue growth and margin expansion as volumes recover.
Baxter's strengthened focus on innovation-including new product launches in advanced infusion systems, AI-enabled devices, and compounding-aligns with growing demand for efficient, digitalized, and connected healthcare equipment, positioning the company to capture higher-margin revenue streams and gain market share.
An aging population and the rising prevalence of chronic diseases are long-term drivers of increased demand for Baxter's critical care, compounding, and advanced surgery products, supporting sustained top-line growth as these demographic shifts accelerate healthcare utilization.
Ongoing portfolio optimization efforts, including divestitures, cost reductions, and a commitment to eliminate stranded costs by 2027, aim to streamline operations, improve efficiency, and drive net margin improvement, which should be reflected in future earnings growth.
The appointment of a new CEO with a track record in operational excellence is expected to accelerate transformation initiatives, refocus the organization on innovation and commercial execution, and support long-term expansion in operating margins and EPS.

Baxter International Earnings and Revenue Growth

Baxter International Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Baxter International's revenue will grow by 3.7% annually over the next 3 years.
Analysts assume that profit margins will increase from -2.3% today to 7.5% in 3 years time.
Analysts expect earnings to reach $913.6 million (and earnings per share of $1.81) by about September 2028, up from $-247.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.0 billion in earnings, and the most bearish expecting $752 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 21.5x on those 2028 earnings, up from -50.8x today. This future PE is lower than the current PE for the US Medical Equipment industry at 29.7x.
Analysts expect the number of shares outstanding to grow by 0.59% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.1%, as per the Simply Wall St company report.

Baxter International Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing hospital IV fluid conservation and a slower-than-anticipated return to historical usage patterns, with management now assuming 20% below-normal levels for the foreseeable future, pose a risk to volume recovery and may limit revenue growth if hospitals do not resume prior practices.
Temporary suspension and quality-related field actions for Novum IQ infusion pumps-amid customer and regulatory scrutiny-raise the risk that the pause could extend or repeat, leading to lost momentum, delayed product launches, and potential market share loss, negatively impacting both revenue and operating margins.
Sustained softness in U.S. injectables and inhaled anesthesia, compounded by unexpected shifts toward alternative administration routes (such as IV push), point to persistent demand weakness and potential product substitution or competitive threats, which could depress pharmaceutical segment sales and overall company revenues.
Margin compression from unfavorable product mix, reduced manufacturing volumes, and ongoing absorption issues in the integrated supply chain have already resulted in lower-than-expected gross and operating margins, which could persist if volume/mix headwinds are not resolved promptly, thus impacting net margin and earnings growth.
The ongoing need to manage and reduce stranded costs post-divestiture (such as the Kidney Care business) synchronized with the phase-out of lucrative TSA income introduces execution risk-if costs are not removed at the same pace as TSA roll-off, there could be a margin gap, further stressing net margins and overall profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $29.0 for Baxter International based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $47.0, and the most bearish reporting a price target of just $19.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $12.1 billion, earnings will come to $913.6 million, and it would be trading on a PE ratio of 21.5x, assuming you use a discount rate of 9.1%.
Given the current share price of $24.45, the analyst price target of $29.0 is 15.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Baxter International?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026